Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 4/20 | 0.64 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.49 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.47 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.47 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.96 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.64 |
| ▸ | KHK | P50053 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263800 | 0.98 | BPTF (1.00) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2706714 | 0.98 | BPTF (1.00) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL928626 | 0.86 | BPTF (0.79) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL17134678 | 0.80 | BPTF (0.63) | BPTFCHRNA7CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15091835 | 0.80 | CHRNB2 (0.65) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL30307836 | 0.80 | BPTF (0.63) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL31323904 | 0.78 | BPTF (0.61) | BPTFCHRNA7CHRNB2CHRNA4KHK | |
| Hydrochloric Acid SCHEMBL26607616 | 0.78 | BPTF (0.61) | BPTFCHRNA7CHRNB2CHRNA4KHK | |
| Hydrochloric Acid SCHEMBL652246 | 0.78 | CHRNB2 (1.00) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL652245 | 0.78 | CHRNB2 (1.00) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-06-24 | — | — | US | disclosed |
| EP-3600290-B1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240300954-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-09-12 | — | — | US | disclosed |
| US-20240300953-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-09-12 | — | — | US | disclosed |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-11807642-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220348581-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | TEMPLE UNIVERITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-11-03 | — | — | US | disclosed |
| US-11220505-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-25 | — | — | US | disclosed |
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200331915-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-10-22 | — | — | US | disclosed |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-06 | — | — | US | disclosed |
| EP-3600290-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3600289-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | Temple University - Of The Commonwealth System of Higher Education (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175190-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175188-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | CHRNA7 161/4885CHRNB4 198/4885CHRNA3 127/4885 |
| US-20200331915-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | HTR7, HTR6, HTR5A | CHRNA7 64/4885CHRNB4 181/4885CHRNA3 146/4885 |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | CHRNA7 148/4885CHRNB4 175/4885CHRNA3 113/4885 |
| US-20220348581-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | HTR7, HTR6, HTR5A | CHRNA7 64/4885CHRNB4 181/4885CHRNA3 146/4885 |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | CHRNA7 148/4885CHRNB4 175/4885CHRNA3 113/4885 |
| US-11807642-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | CHRNA7 64/4885CHRNB4 181/4885CHRNA3 146/4885 |
| US-11220505-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | CHRNA7 64/4885CHRNB4 181/4885CHRNA3 146/4885 |
| US-20240300953-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | HTR7, HTR6, HTR5A | CHRNA7 64/4885CHRNB4 181/4885CHRNA3 146/4885 |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | CHRNA7 161/4885CHRNB4 198/4885CHRNA3 127/4885 |
| US-20240300954-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | CHRNA7 148/4885CHRNB4 175/4885CHRNA3 113/4885 |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | CHRNA7 64/4885CHRNB4 181/4885CHRNA3 146/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | CHRNA7 14/4885CHRNB4 42/4885CHRNA3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.